$AUTL

Autolus Therapeutics plc

  • NASDAQ
  • Health Technology
  • Biotechnology
  • Manufacturing
  • Biological Product (except Diagnostic) Manufacturing

PRICE

$2.62 -

Extented Hours

VOLUME

194,847

DAY RANGE

2.505 - 2.71

52 WEEK

2.2 - 8.23

Join Discuss about AUTL with like-minded investors

profile
@dros #droscrew
recently

400 $AUTL JAN2022 $7.5 Cs trade 0.7

114 Replies 11 👍 9 🔥

profile
@Math #StockTraders.NET
recently

on small caps I got $PROG $AUTL $PPSI short

64 Replies 15 👍 12 🔥

profile
@maletone #StockTraders.NET
recently

$AUTL on watch

132 Replies 7 👍 10 🔥

profile
@maletone #StockTraders.NET
recently

$AUTL atlas was buying the dip

110 Replies 14 👍 7 🔥

profile
@maletone #StockTraders.NET
recently

got bigger plays like $DLPN, $AUTL

57 Replies 14 👍 10 🔥

profile
@maletone #StockTraders.NET
recently

$AUTL might be a all day fader

56 Replies 14 👍 6 🔥

profile
@viking #StockTraders.NET
recently

Upside: -NOVN +32% (reports positive topline results from pivotal Phase III trial of SB206 in patients with molluscum contagiosum) -PGEN +28% (announces positive topline results from Phase 1b/2a study of AG019 ActoBiotics, a Novel Therapy designed to address the underlying cause of Type 1 Diabetes; primary endpoints were met) -GENE +15% (US Patent Office grants foundational pharmacogenomic patent) -MX +15% (confirms 21% improved rival bid of $35/shr cash unsolicited proposal from Cornucopia Investment Partners) -ZDGE +9.5% (earnings, guidance) -ATC +8.4% (MKS Instruments said to have approached Atotech for acquisition) -ADMP +5.9% (provides update on clinical trial start-up progress for tempol in the treatment of COVID-19) -RFP +5.6% (announces $1/share Special Dividend, and $50M in lumber investments) -PLAY +5.3% (earnings, guidance) -AUTL +5.1% (presents new data on obe-cel in r/r Indolent B cell lymphomas and gives an update of obe-cel in r/r Adult ALL at the European Hematology Association Virtual Congress) -MBIO +5.0% (announced updated interim Phase 1/2 data for MB-106) -TYME +5.0% (comprehensive strategic review identified breast cancer as a priority indication for development, a focus on second-line pancreatic cancer, and continuation of trial in high-risk sarcomas) -LIFE +2.5% (presents poster demonstrating functional selectivity of second Anti-NRP2 Antibody) -OCGN +1.4% (Roth Capital broker downgrade) -AVO +1.3% (earnings, guidance) Downside: -ORPH -52% (application for MIPLYFFA under priority review with FDA, expected Prescription Drug User Fee Act action date of June 17; company not aware for reason for stock volatility) -VRTX -14% (reports primary endpoint achieved in Phase 2 Study of VX-864 in Alpha-1 Antitrypsin Deficiency but magnitude of treatment effect observed unlikely to translate into substantial clinical benefit) -CVAC -11% (downside momentum) -INCY -4.0% (FDA extendes the New Drug Application review period for ruxolitinib cream for the treatment of atopic dermatitis) -ADC -3.9% (prices 4.0M shares at implied $71.50/shr to raise $286M) -SNOW -3.7% (provides 2029 financial targets) -ELY -3.6% (to join S&P MidCap 400) -LTHM -3.2% (prices 13M shares at $17.50/shr) -AGNC -3.1% (reports tangible net book value) -RCL -2.1% (two guests aboard Celebrity Millennium test positive for COVID during required end-of-cruise testing) -CHWY -1.4% (earnings, guidance)

106 Replies 14 👍 13 🔥

profile
@maletone #StockTraders.NET
recently

$LHDX, $EYES, $CRIS $AUTl will be on watch tomorrow

84 Replies 13 👍 7 🔥

Key Metrics

Market Cap

238.18 M

Beta

0.98

Avg. Volume

218.03 K

Shares Outstanding

90.91 M

Yield

0%

Public Float

0

Next Earnings Date

2022-08-04

Next Dividend Date

Company Information

Autolus Therapeutics plcis a clinical-stage biopharmaceutical company developing next-generation, programmed T cell therapies for the treatment of cancer. Using a broad suite of proprietary and modular T cell programming technologies, the company is engineering precisely targeted, controlled and highly active T cell therapies that are designed to better recognize cancer cells, break down their defense mechanisms and eliminate these cells. Autolus has a pipeline of product candidates in development for the treatment of hematological malignancies and solid tumors.

Website:

HQ: Scale Space Building 58 Wood Lane, W12 7RZ London

Related News